US Patent Issued to Amgen on Feb. 24 for "Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy" (California, New Jersey Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,560,596, issued on Feb. 24, was assigned to Amgen Inc. (Thousand Oaks, Calif.).

"Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy" was invented by Theresa Rosario-Jansen (Randolph, N.J.) and David Erick Wright (Ramona, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit f...